Test drug OP-1250 with other medicines in ER-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 1b study tests OP-1250 (palazestrant) combined with other targeted medicines for ER-positive, HER2-negative advanced or metastatic breast cancer. It mainly looks at safety and correct dosing, but may also help shrink tumors or slow growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older and able to follow all study visits and procedures
- Have advanced or metastatic breast cancer confirmed by a pathology test (biopsy or scan sample)
- Your cancer must be ER-positive and HER2-negative based on your most recent tumor testing
- Have at least one measurable tumor spot, or mostly bone tumors that can be followed on scans
- Generally be well enough to do daily activities (ECOG 0–1) and expected to live at least 6 months
- Have limited prior treatment: no more than 1 prior hormone treatment (or up to 2 in some groups) and no more than 1 prior chemotherapy for metastatic disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, OP-3136, alone or with other drugs, for people with advanced breast cancer, prostate cancer, or lung cancer that has stopped responding to other treatments. It aims to see if OP-3136 is safe and effective.
This trial tests a new drug (palazestrant) combined with ribociclib for people with a common type of advanced breast cancer that is estrogen receptor-positive and HER2-negative. You may qualify if you haven't had treatment for advanced disease and your cancer has either just been found or came back long after completing hormone therapy.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
This Phase 1 trial tests a combination of immune-targeting drugs (a CD40 medicine and a substance that helps immune cells act) plus chemotherapy in people with HER2-negative advanced breast cancer that has progressed. It aims to find a safer dose and see whether the treatment can shrink tumors or slow the cancer.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.